Pfizer Shares Fall on Weak 2026 Profit Outlook
Pfizer shares tumbled after the drugmaker projected flat revenues and lower profits for 2026, citing declining Covid-19 sales and heavy investment in new products like weight-loss drugs.
Category : Search result: Metsera
Pfizer buys Metsera in $10bn weight loss drug deal
Pfizer completes Metsera acquisition worth up to $10 billion, entering the competitive weight loss drug market. Learn how this deal positions Pfizer against Novo Nordisk.
Novo Nordisk vs Pfizer: Bidding War for Obesity Drugmaker
Major pharmaceutical battle intensifies as Novo Nordisk challenges Pfizer in high-stakes acquisition race for obesity treatment specialist Metsera, reshaping the weight-loss drug market.
Page 1 of 1